Table 3.
Treatment-related toxicity
| Toxicity | Paclitaxel/carboplatin/sorafenib (N = 43) | Paclitaxel/carboplatin (N = 42) | ||
|---|---|---|---|---|
| Grade 1/2 | Grade 3/4 | Grade 1/2 | Grade 3/4 | |
| Hematologic | ||||
| Neutropenia | 17 (40%) | 11 (26%) | 20 (48%) | 13 (31%) |
| Anemia | 22 (51%) | 7 (16%) | 25 (59%) | 5 (12%) |
| Thrombocytopenia | 17 (40%) | 9 (21%) | 22 (52%) | 3 (7%) |
| Febrile neutropenia | 2 (5%) | 1 (2%) | 0 | 1 (2%) |
| Nonhematologic | ||||
| Nausea/vomiting | 30 (70%) | 3 (7%) | 34 (81%) | 3 (7%) |
| Peripheral neuropathy | 25 (58%) | 6 (14%) | 25 (58%) | 3 (7%) |
| Fatigue | 26 (60%) | 3 (7%) | 29 (69%) | 3 (7%) |
| Skin rash | 27 (63%) | 14 (33%) | 2 (5%) | 1 (2%) |
| Diarrhea | 20 (47%) | 2 (5%) | 7 (17%) | 1 (2%) |
| Pain-muscle | 12 (28%) | 0 | 14 (33%) | 0 |
| Hypersensitivity reaction (paclitaxel) | 2 (5%) | 4 (9%) | 0 | 1 (2%) |
| Mucositis | 16 (37%) | 0 | 7 (17%) | 0 |
| Constipation | 7 (16%) | 0 | 14 (33%) | 0 |
| Pain-joint | 9 (21%) | 0 | 11 (26%) | 0 |
| Anorexia | 9 (21%) | 0 | 8 (19%) | 0 |
| Hand–foot syndrome | 12 (28%) | 4 (9%) | 0 | 0 |
| Abdominal pain | 6 (14%) | 3 (7%) | 2 (5%) | 3 (7%) |
| Weakness | 7 (16%) | 0 | 6 (14%) | 0 |
| Hypertension | 8 (19%) | 2 (5%) | 2 (5%) | 0 |
| Dizziness | 6 (14%) | 0 | 6 (14%) | 0 |
| Fever (no neutropenia) | 6 (14%) | 0 | 5 (12%) | 0 |
| Dehydration | 4 (9%) | 1 (2%) | 1 (2%) | 3 (7%) |
| Dyspnea | 3 (7%) | 0 | 5 (12%) | 0 |
| Headache | 5 (12%) | 0 | 3 (7%) | 0 |
| Edema | 3 (7%) | 0 | 2 (5%) | 0 |
| Hyponatremia | 0 | 4 (9%) | 0 | 0 |
| Pruritus | 3 (7%) | 0 | 1 (2%) | 0 |
| Treatment-related hospitalizations | 6 (14%) | 6 (14%) | ||
| Treatment-related deaths | 0 | 0 | ||